key: cord-0782374-017gog1x
authors: Patibandla, A.; Featherstone, C.; Maclaren, V.; Lumsden, G.; Harrow, S.; Jones, R.; Chalmers, A.J.; McLoone, P.; Hicks, J.
title: Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience
date: 2020-07-11
journal: Clin Oncol (R Coll Radiol)
DOI: 10.1016/j.clon.2020.06.006
sha: 7a9db75922129c379ef7f2b2ee902fdfc88e4d5c
doc_id: 782374
cord_uid: 017gog1x

nan

.

All 163 stage III A/B NSCLC patients who received this regimen between January 2012 and December 2016 were included. Data were censored on 31 March 2018. KaplaneMeier analysis was used to estimate 1-, 2-and 3year survival rates and the median overall survival. The median follow-up was 38 months.

Our data allay concerns over the delivery of chemotherapy concurrently with hypofractionated radiotherapy and confirm the efficacy of the SOCCAR regimen. Only 3% of our patients did not complete the planned radiotherapy and 76% received both cycles of concurrent chemotherapy. There were no 30-or 90-day treatment-related deaths. The median overall survival was 31.2 months; 1-, 2-and 3-year survival rates were 75, 56 and 45%, respectively.

To our knowledge this is the largest series of patients treated with this regimen; a number similar to the control arm of RTOG 0617. The median survival of 31.2 months in this real-life population outperforms all the 2 Gy per fraction arms delivering 60e66 Gy in recently published trial populations prior to the use of adjuvant immunotherapy. The median survival in the control arm of RTOG 0617 was 28.7 months [3] . The median survival was 25 and 26.8 months in the arms of the PROCLAIM trial [4] and 29.1 months in the control arm of PACIFIC [5] .

Our findings validate a smaller series that reported a median survival of 43 months in patients treated with the SOCCAR regimen [6] and support the use of moderately hypofractionated radiotherapy with concomitant chemotherapy in patients with stage III NSCLC.

Authors declare no conflicts of interest. 

Reduced fractionation in lung cancer patients treated with curative-intent radiotherapy during the COVID-19 pandemic

SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

PROCLAIM: randomized phase III trial of pemetrexedcisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced non-squamous non-small-cell lung cancer

Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-Update From PACIFIC

Hypofractionated concomitant chemoradiation in inoperable locally advanced non-small cell lung cancer: a report on 100 patients and a systematic review

0936-6555/Ó 2020 The Royal College of Radiologists

Hypofractionated Accelerated Concurrent Chemoradiotherapy in Inoperable Stage III Non-small Cell Lung Cancer: SOCCAR. A Large Single-Centre Experience